Skip to main content

Table 1 Characteristics of the study population (n = 275)

From: Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis

Parameter Value
Age (years)a 44 (42–48)
Male gender, no. (%) 245 (89)
Daily alcohol intake > 50 grs/day, no. (%) 40 (14)
Previous intravenous drug users, no. (%) 250 (91)
Previous therapy against HCV, no (%) 57 (21)
HCV genotype, no. (%)b  
 1 165 (61)
 2 2 (1)
 3 61 (23)
 4 41 (15)
HCV RNA load (log10 IU/mL)a,c 6.17 (5.68–6.69)
Positive hepatitis B virus surface antigen, no (%) 8 (3)
Serum alanine aminotransferase (IU/L)a 74 (48–105)
Serum aspartate aminotransferase (IU/L)a 72 (47–104)
Total bilirrubin (mg/dL)a 0.7 (0.5–1.02)
Platelet count (/mm3)a 130000 (94000–171750)
HIV RNA load < 50 copies/mL, no. (%) 184 (67)
CD4 cells/mLa 459 (265–626)
ARTd, no (%) 256 (83)
MELDe scorea,f 7 (6–9)
Child-Turcotte-Pugh class, no (%)  
 A 248 (90)
 B 27 (10)
Liver stiffness (kPa)a 20 (17–27)
  1. aMedian (Q1-Q3)
  2. Available in b269 and
  3. c254 patients
  4. dART: Antiretroviral therapy
  5. eMELD: Model for end-stage liver disease
  6. fAvailable in 251 patients